The medication is a systemic agent commonly used to manage conditions characterized by periods of heightened symptoms that interfere with daily functioning. Its therapeutic scope is primarily aligned with conditions where symptoms may intensify temporarily, contributing to easing the overall symptom load across key domains.

---

Therapeutic Focus and Symptom Support

Deflazacort is considered relevant across domains where additional symptomatic support is needed, primarily addressing progressive neuromuscular disorders like Duchenne Muscular Dystrophy (DMD), chronic autoimmune conditions such as Rheumatoid Arthritis and Systemic Lupus Erythematosus, and severe inflammatory manifestations like Bronchial Asthma or Nephrotic Syndrome.

Supportive Benefit

For patients dealing with muscle deterioration, the medication provides supportive relief when symptoms create noticeable physiological strain, which assists with maintaining functional stability. For those with systemic inflammation, it is used for managing symptom clusters that may become intense or disruptive, and supports patients during difficult episodes by easing discomfort.

---

Quick Fact: Relief for Symptomatic Strain
Supports patients during phases of increased systemic discomfort and helps address symptoms related to inflammatory or irritative states where functional stability becomes affected.

---

Summary of Uses

The medication is commonly used to help with symptoms related to systemic imbalance and symptoms of increased neurological or muscular activity, offering therapeutic support across these challenging symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Deflazacort eligibility is determined by specific regulatory criteria related to age, physiological status, and underlying conditions, as defined in official prescribing information.

---

Contraindications and Exclusions

Classification	Rule
Absolute Contraindication	Patients with known hypersensitivity to deflazacort or any inactive ingredients.
Infection Status	Contraindicated in patients with systemic fungal infections.
Vaccination	Live or live attenuated vaccines should not be administered to patients receiving immunosuppressive doses of deflazacort.

---

Age and Condition-Based Eligibility

• Age: The medicine is officially indicated for patients 2 years of age and older. Safety and efficacy have not been established in patients younger than 2 years. Geriatric data is limited.
• Hepatic Impairment: Use is not established in patients with severe hepatic impairment, as dosing recommendations are unavailable for this group. No dosage adjustments are needed for mild or moderate hepatic impairment.
• Renal Impairment: No dosage adjustments are needed for patients with mild, moderate, or severe renal impairment.
• Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. The drug and its active metabolite are present in human milk.

The active component of deflazacort is metabolized by the liver enzyme CYP3A4, which is the primary basis for key drug interactions.

Pharmacokinetic Interactions

Interacting Product Category	Official Constraint/Requirement
Moderate or Strong CYP3A4 Inhibitors (e.g., clarithromycin, diltiazem)	Required Dose Adjustment: The deflazacort dosage must be reduced to one third (1/3) of the prescribed dose to manage the risk of increased systemic exposure and potential toxicity.
Moderate or Strong CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine)	Avoid Combination: Concomitant use should be avoided due to the risk of significantly decreased exposure of the active metabolite, which may result in a loss of drug efficacy.
Grapefruit or Grapefruit Juice	Avoid Use (Effect similar to CYP3A4 inhibitors).

Pharmacodynamic and Other Interactions

• Live Vaccines: Live or live attenuated vaccines must not be administered to patients receiving immunosuppressive doses of deflazacort. The immune response to other vaccines may also be reduced.
• Antidiabetic Drugs: Corticosteroids like deflazacort can reduce the effect of antidiabetic medicines, which necessitates monitoring of blood glucose levels.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant use with NSAIDs increases the risk of gastrointestinal ulcers.
• Potassium-Depleting Agents: Combination with loop or thiazide diuretics may increase the risk of low potassium levels (hypokalemia).
• Oral Contraceptives/Estrogens: The effect of deflazacort may be increased in women taking estrogens; a reduction in the deflazacort dose may be necessary.

Deflazacort acts as a synthetic agonist of the glucocorticoid receptor (GR). Its primary mechanism of action begins with binding to the cytoplasmic GR. This binding stabilizes the GR-ligand complex, which subsequently translocates into the cell nucleus. The activated complex mediates its effects through dual genomic and non-genomic actions.

In the nucleus, the complex modulates gene expression. It binds to Glucocorticoid Response Elements (GREs) in the promoter regions of target genes, thereby inducing the transcription of anti-inflammatory proteins, which leads to the altered expression of inflammatory mediators. Concurrently, it suppresses the transcription of pro-inflammatory genes by interfering with transcription factors such as NF-kappaB and AP-1. This signaling also influences the ratio of osteoclast to osteoblast activity, resulting in reduced bone resorption relative to formation.

The administration of Deflazacort is strictly by the oral route, using either the tablet (6 mg, 18 mg, 30 mg, or 36 mg) or the oral suspension formulation (22.75 mg/mL). The medicine is taken once daily (qDay) and may be consumed with or without food. Dosing is generally conducted in the morning to align with the body’s natural steroid cycle.

Official Dosing and Administration Rules

Dosage Regimens

The standard oral regimen for the treatment of Duchenne Muscular Dystrophy (DMD) in patients two years of age and older is approximately 0.9 mg/kg/day (milligrams per kilogram of body weight per day). The dose must be calculated based on the patient's weight. If tablets are used, the dose should be rounded up to the nearest possible tablet combination; if the oral suspension is used, the volume must be rounded up to the nearest tenth of a milliliter.

Preparation and Timing

Tablets may be swallowed whole or can be crushed and mixed with applesauce for immediate consumption. The oral suspension must be shaken well and then mixed into three to four ounces of juice or milk before being administered right away; the suspension should not be mixed with grapefruit juice.

Procedural Conditions and Discontinuation

If a dose is missed, it should be taken as soon as the patient remembers; however, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should not take two doses at once. It is established that if the medicine has been taken for more than a few days, the dose must be gradually reduced (tapered) before full discontinuation. Furthermore, the recommended dose must be reduced to one-third if co-administered with moderate or strong CYP3A4 inhibitors.

Research Evidence Overview

Deflazacort is a corticosteroid approved for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older. Research has focused on its potential to slow the progression of muscle weakness and preserve physical function over time.

Efficacy Studies

Clinical trials have evaluated deflazacort's effect on muscle strength and function compared to placebo.

• Primary Outcome: In one Phase III, placebo-controlled study, participants receiving deflazacort demonstrated a statistically significant improvement in average muscle strength score at 12 weeks compared to the placebo group.
• Functional Measures: Studies have investigated functional outcomes such as the time taken to climb four stairs and the 6-minute walk distance (6MWD). Analyses of trial data have indicated a lower rate of functional decline over 48 weeks for deflazacort-treated patients compared to a control group.

Comparative Findings and Safety Profile

Limited direct comparative studies exist; however, some meta-analyses and post-hoc comparisons have examined deflazacort against prednisone/prednisolone, another corticosteroid used in DMD management.

Outcome Category	Finding in Deflazacort-Treated Patients (vs. Prednisone)
Weight Gain	Less weight gain was reported.
Behavioral Changes	Fewer instances of psychiatric adverse events (e.g., aggression, irritability) were reported.
Growth/Bone Health	Some studies noted a potentially greater impact on growth reduction and a risk of cataract formation and fractures with long-term use.

Safety Data: The most common adverse reactions reported in clinical trials for deflazacort (occurring in ge 10% of patients and greater than placebo) include Cushingoid appearance, increased weight and appetite, upper respiratory tract infection, and cough. The long-term safety profile requires ongoing monitoring, particularly concerning growth and bone density.

Common questions about Deflazacort (FAQ)

---

Q: What should I do if I miss a dose of Deflazacort?

Official prescribing information advises that if a dose is missed, it is advised that the dose be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance indicates that the missed dose should be skipped, and the person should resume the regular schedule. It is important that two doses are not taken at once to make up for the missed one.

---

Q: What is the maximum daily dose of Deflazacort?

According to the official regulatory documents, the recommended dose is typically calculated based on the patient's weight, approximately 0.9 mg/kg once daily. The prescribing information specifies this weight-based calculation but does not set an absolute maximum milligram amount (a cap) that a person can take in a day, regardless of their weight.

---

Q: What is the shelf life of the oral suspension once it has been opened?

The official storage guidelines state that after the Deflazacort oral suspension bottle is first opened, any unused medicine remaining in the bottle must be discarded after one month. Following this rule is important for maintaining the medication's stability and consistency during the period it is used.

---

Q: Can I mix the oral suspension with other liquids?

Official preparation instructions specify mixing the oral suspension into three to four ounces (90 to 120 mL) of either milk or a fruit juice, excluding grapefruit juice, for immediate administration. The regulatory labeling does not provide information or instruction for mixing the suspension with any other types of liquids, such as water or soda.

---

Q: Are there any dietary restrictions I need to follow while taking this medication?

Official labeling advises against the consumption of grapefruit and grapefruit juice, as these products may increase the amount of the drug in the body, which could lead to increased exposure. For corticosteroids generally, a healthcare provider may also advise on dietary salt restriction or potassium supplementation for certain patients to manage potential side effects.

How to Store and Dispose of Deflazacort?

Official Storage Conditions

Deflazacort tablets and oral suspension must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The medication must be kept in its tightly closed container and stored out of the sight and reach of children.

Protection and Stability

The product must be protected from freezing and stored away from excess heat, moisture, and direct light. The oral suspension bottle must be kept stored upright. The oral suspension has a defined in-use stability period: any unused portion remaining in the bottle must be discarded after one month of first opening.

Disposal Requirements

Official labeling instructs that unused or expired deflazacort should not be kept. Patients should consult a healthcare professional or pharmacist for specific guidance on how to properly dispose of any unneeded medicine.